AbbVie subsidiary Allergan will pay about US$30 million to resolve the remainder of a consolidated antitrust class action over its alleged scheme to delay generic versions of the dry-eye treatment Restasis, according to a federal court filing in Brooklyn.
The insurers and pension funds leading part of the lawsuit sought preliminary approval from Judge Nina Gershon for the US$29,999,999.99 settlement on behalf of “end payers” that completely or partially covered consumer sales of the drug.
The October 8 request comes about four months after Gershon paused the case while the two sides hammered out a final deal.
The proposed class action settlement was disclosed in a filing on Tuesday, October 12, in federal court in Brooklyn and would resolve claims by direct purchasers of Restasis such as wholesalers who claimed that Allergan’s actions led them to be overcharged for the drug.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Chamber of Commerce Sues to Overturn FTC Non-Compete Ban
Apr 24, 2024 by
CPI
FTC Chief Warns of Healthcare Price Fixing Risks Amid Tech Advancements
Apr 24, 2024 by
CPI
Amazon’s Investment in Anthropic Faces Antitrust Scrutiny
Apr 24, 2024 by
CPI
Italian Antitrust Authority Fines Amazon €10 Million for Unfair Trade Practices
Apr 24, 2024 by
CPI
Tuta Mail Raises Alarm Over Google Search Ranking Plunge Amidst DMA Rollout
Apr 24, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI